Pharma Reviews: $23 Billion Fund Sees More Gains in Costly Indian Developers

$23 Billion Fund Sees More Gains in Costly Indian Developers ... “Indian pharma companies are building a strong product portfolio for post-2020.
Read more: $23 Billion Fund Sees More Gains in Costly Indian Developers